HOCPF:OTC-HOYA Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 122

Change

0.00 (0.00)%

Market Cap

USD 43.50B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 102.50B
ESLOY Essilor International SA

N/A

USD 101.63B
HOCPY Hoya Corp

N/A

USD 40.66B
RSMDF Resmed Inc DRC

N/A

USD 31.10B
CLPBF Coloplast A/S

N/A

USD 27.05B
CLPBY Coloplast A

N/A

USD 26.98B
TRUMF Terumo Corporation

N/A

USD 26.03B
TRUMY Terumo Corp ADR

N/A

USD 24.81B
SAUHF Straumann Holding AG

N/A

USD 21.26B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 21.15B

ETFs Containing HOCPF

DBJP Xtrackers MSCI Japan Hedg.. 0.00 % 0.47 %

N/A

USD 0.43B
DXJH 0.00 % 0.48 %

N/A

N/A
EWJ iShares MSCI Japan ETF 0.00 % 0.47 %

N/A

USD 15.50B
FLJH Franklin FTSE Japan Hedge.. 0.00 % 0.09 %

N/A

USD 0.07B
FLJP Franklin FTSE Japan ETF 0.00 % 0.09 %

N/A

USD 2.11B
CSJP:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 0.62B
HMJD:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

N/A

USD 0.19B
HMJP:LSE HSBC MSCI JAPAN UCITS ETF 0.00 % 0.00 %

N/A

USD 0.19B
IJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

N/A

USD 3.63B
IJPD:LSE iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 0.42B
IJPE:LSE iShares MSCI Japan EUR He.. 0.00 % 0.00 %

N/A

USD 0.70B
IJPN:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

N/A

USD 1.10B
IJPU:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

N/A

USD 1.10B
JPEH:LSE SPDR® MSCI Japan EUR Hdg.. 0.00 % 0.00 %

N/A

USD 0.04B
JPJP:LSE SPDR® MSCI Japan UCITS E.. 0.00 % 0.00 %

N/A

USD 94.00B
JPXG:LSE 0.00 % 0.00 %

N/A

N/A
JPXU:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

N/A

USD 0.01B
JPXX:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

N/A

USD 9.86M
LCJD:LSE Amundi MSCI Japan (DR) UC.. 0.00 % 0.00 %

N/A

USD 553.83B
LCJG:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

N/A

USD 0.04B
LCJP:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

N/A

USD 553.83B
SJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

N/A

USD 5.37B
IJPH:LSE iShares MSCI Japan GBP He.. 0.00 % 0.00 %

N/A

USD 0.12B
UB02:LSE UBS MSCI Japan UCITS JPY .. 0.00 % 0.00 %

N/A

USD 114.95B
UB0D:LSE UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.16B
UC65:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.00 %

N/A

USD 115.48B
XDNG:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

N/A

USD 0.01B
XDNS:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

N/A

USD 56.67B
XDNU:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

N/A

USD 3.63M
XDNY:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

N/A

USD 56.67B
XMJD:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

N/A

USD 2.81B
XMJG:LSE 0.00 % 0.00 %

N/A

N/A
XMJP:LSE Xtrackers MSCI Japan UCIT.. 0.00 % 0.00 %

N/A

USD 2.81B
XMUJ:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

N/A

USD 0.14B
UB0C:LSE 0.00 % 0.00 %

N/A

N/A
CJPU:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 0.62B
SAJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

N/A

USD 1.47B
SDJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

N/A

USD 0.49B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.44% 72% C 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.44% 70% C- 60% D-
Trailing 12 Months  
Capital Gain 3.35% 75% C 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.35% 71% C- 59% D-
Trailing 5 Years  
Capital Gain 72.56% 92% A 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.56% 90% A- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.62% 60% D- 58% F
Dividend Return 11.62% 52% F 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.16% 81% B- 76% C+
Risk Adjusted Return 42.79% 85% B 81% B-
Market Capitalization 43.50B 96% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector